Studying how non-small cell lung cancer progresses
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how non-small cell lung cancer develops and changes over time. It may help doctors better understand the disease and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been diagnosed with non-small cell lung cancer and are receiving care at Bordeaux University Hospital.
- Your cancer is at any stage, from stage I to stage IV.
- You are covered by a health insurance plan (social security).
- You have not had another type of cancer (aside from certain low-risk skin or early-stage cancers) in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This trial does not test a new drug. It looks at existing medical records to compare how well different treatments work for people with advanced non-small cell lung cancer. You may be eligible if your cancer is advanced and you are not in another clinical trial.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study looks at how lung cancer changes over time by analyzing tumor tissue and blood. It may help researchers understand what drives cancer relapse after early-stage surgery.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.